Nucl Med Mol Imaging 2018 Feb 11;52(1):80-81. Epub 2018 Jan 11.
1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.
Download full-text PDF
J Nucl Med 2017 Mar 22;58(3):445-450. Epub 2016 Sep 22.
Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed doses for normal organs and tumor lesions using Lu-PSMA I&T (I&T is imaging and therapy) in patients undergoing up to 4 cycles of radioligand therapy. Results were compared with pretherapeutic Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBEDCC)] (Ga-PSMA-HBED-CC) PET. Read More
Eur J Nucl Med Mol Imaging 2015 Dec 31;42(13):1976-83. Epub 2015 Jul 31.
Department of Nuclear Medicine, Yeditepe University Medical Faculty, Istanbul, Turkey.
Purpose: (177)Lu-617-prostate-specific membrane antigen (PSMA) ligand seems to be a promising tracer for radionuclide therapy of progressive prostate cancer. However, there are no published data regarding the radiation dose given to the normal tissues. The aim of the present study was to estimate the pretreatment radiation doses in patients who will undergo radiometabolic therapy using a tracer amount of (177)Lu-labeled PSMA ligand. Read More
Nucl Med Commun 2017 Jan;38(1):91-98
Departments of aNuclear Medicine bMedical Oncology cUrology, All India Institute of Medical Sciences, New Delhi, India.
Objective: Lu-DKFZ-PSMA-617, a urea-based compound, binds to the extracellular domain of prostate-specific membrane antigen, thus providing an effective target for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Before its therapeutic use, it is necessary that the radiation dosimetry of this radiopharmaceutical be studied to determine the safe activity that can be administered in patients to prevent haematological, renal and liver toxicity. The present study thus aimed to assess the pharmacokinetics and dosimetry of Lu-DKFZ-PSMA-617 in CRPC patients. Read More
EJNMMI Res 2018 Jul 3;8(1):56. Epub 2018 Jul 3.
Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
Background: External cooling of the salivary glands is advised to prevent xerostomia in lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this subject is sparse, this study aims to determine impact of icepacks application on uptake in salivary glands. Eighty-nine patients referred for gallium-68-PSMA PET/CT for (re)staging of prostate cancer were prospectively included. Read More